Carotuximab, also known as TRC105 and DE-122, represents a unique antibody-drug conjugate therapeutic currently under investigation for managing various oncological conditions. This specific molecule selects a defined https://deborahycep131118.blog5.net/92518251/carotuximab-trc105-de-122-a-deep-dive